404
|
Total cholesterol
|
Metabolites
|
Humans
|
Downregulated with Low Fat Diet [ Control Diet: 196 (95% CI: 180-226), Low Fat Diet: 182 (95% CI: 161-192)]
|
Predictive
|
Controls Vs Low Fat Supplementation in patients with PCa
|
p = 0.048
|
Blood
|
19064574
|
405
|
Low-density cholesterol
|
Metabolites
|
Humans
|
Downregulated with Low Fat Diet [ Control Diet: 111 (95% CI: 90-128), Low Fat Diet: 105 (95% CI: 90-124)]
|
Predictive
|
Controls Vs Low Fat Supplementation in patients with PCa
|
p=0.032
|
Blood
|
19064574
|
447
|
CTC (Circulating Tumor Cells)
|
Others
|
Humans
|
Increased expression in overall survival
|
Prognostic
|
Overall Survival Vs No Survival
|
p<0.001
|
Blood
|
19505924
|
448
|
Alkaline Phosphatase
|
Metabolites
|
Humans
|
Increased expression in overall survival
|
Prognostic
|
Overall Survival Vs No Survival
|
p<0.001
|
Blood
|
19505924
|
449
|
LDH
|
Metabolites
|
Humans
|
Increased expression in overall survival
|
Prognostic
|
Overall Survival Vs No Survival
|
p<0.001
|
Blood
|
19505924
|
450
|
Prostatic Acid Phosphatase (PAP)
|
Metabolites
|
Humans
|
Increased expression in overall survival
|
Prognostic
|
Overall Survival Vs No Survival
|
p<0.001
|
Blood
|
19505924
|
451
|
Total Acid Phosphatase (TAP)
|
Metabolites
|
Humans
|
Increased expression in overall survival
|
Prognostic
|
Overall Survival Vs No Survival
|
p<0.001
|
Blood
|
19505924
|
452
|
Albumin
|
Metabolites
|
Humans
|
Increased expression in overall survival
|
Prognostic
|
Overall Survival Vs No Survival
|
p=0.002
|
Blood
|
19505924
|
453
|
Hemoglobin
|
Metabolites
|
Humans
|
Increased expression in overall survival
|
Prognostic
|
Overall Survival Vs No Survival
|
p<0.001
|
Blood
|
19505924
|
456
|
MIC-1 (Macrophage inhibitory cytokine 1)
|
Protein
|
Humans
|
Downregulated after one round of chemotherapy
|
Predictive
|
Metastatic HRPC patients Pre Vs Post One round of Docetaxel chemotherapy
|
p=0.02
|
Blood
|
19773444
|
457
|
MIC-1 (Macrophage inhibitory cytokine 1)
|
Protein
|
Humans
|
Downregulated after one round of chemotherapy
|
Predictive
|
Overall survival Vs No survival in patients Post One round of Docetaxel chemotherapy
|
p=0.002
|
Blood
|
19773444
|
509
|
TRPM8 (transient receptor potential member 8)
|
mRNA
|
Humans
|
Upregulated in Metastatis (Metastatis: 1.81±0.153; Healthy: 1.0 ± 0.132)
|
Diagnostic
|
Healthy Vs Metastatic
|
p<0.001
|
Blood
|
20043080
|
533
|
PSA (G/G Genotype)
|
Mutation
|
Humans
|
Increases risk with G/G Genotype compared with the G/A And A/A genotype
|
Diagnostic
|
Cancer Vs Controls
|
p<0.05
|
Blood
|
20632874
|
534
|
AR: (Short CAG)
|
Mutation
|
Humans
|
Increased Risk with shorter CAG Repeats
|
Diagnostic
|
Cancer Vs Controls
|
p = 0.007
|
Blood
|
20632874
|
535
|
PSA and AR (G/G and Short CAG)
|
Mutation
|
Humans
|
Increased Risk of Prostate Cancer
|
Diagnostic
|
Cancer Vs Controls
|
p = 0.0418
|
Blood
|
20632874
|
536
|
PSA (G/G Genotype)
|
Mutation
|
Humans
|
Increases risk of Gleason Score >=7 with G/G Genotype compared with the G/A & A/A genotype
|
Prognostic
|
Gleason ≤7 Vs Gleason Score >7
|
p= 0.0122
|
Blood
|
20632874
|
537
|
AR: (Short CAG)
|
Mutation
|
Humans
|
Increased RIsk of GS (4+3) with Short CAG Repeats
|
Prognostic
|
Gleason Score 7 (4+3) Vs Gleason Score 7 (3+4)
|
p = 0.045
|
Blood
|
20632874
|
569
|
D-Dimer
|
Protein
|
Humans
|
Upregulated in Progressive Disease
|
Prognostic
|
progressive disease (PD) Vs nonprogressive disease (non-PD)
|
p<0.024
|
Blood
|
21088161
|
585
|
SLCO2B1 (SNP rs12422149)
|
Mutation
|
Humans
|
Increased risk in GA or AA type allele
|
Prognostic
|
Prostate Cancer Specific Mortality No No mortality
|
p<0.05
|
Blood
|
21266523
|
586
|
SLCO1B3 (SNP rs4149117)
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Prostate Cancer Specific Mortality No No mortality
|
p<0.05
|
Blood
|
21266523
|
615
|
Mutation Status of TNFSF10 (SNP: rs3774315 (A/G))
|
Mutation
|
Humans
|
Associated with Disease Aggressiveness
|
Diagnostic
|
More Aggressive Vs Controls
|
Discovery Set: 0.0000734; Testing Set: p=0.03
|
Blood
|
21467234
|
616
|
Mutation Status of FBXO34 (SNP: rs8015211 (T/C))
|
Mutation
|
Humans
|
Associated with Disease Aggressiveness
|
Diagnostic
|
More Aggressive Vs Controls
|
Discovery Set: p= 0.0000164
|
Blood
|
21467234
|
617
|
Mutation Status of FBXO34 (SNP: rs12433615 (A/G))
|
Mutation
|
Humans
|
Associated with Disease Aggressiveness
|
Diagnostic
|
More Aggressive Vs Controls
|
Discovery Set: p= 0.0000406
|
Blood
|
21467234
|
618
|
Mutation Status of FBXO34 (SNP: rs1188069 (T/G))
|
Mutation
|
Humans
|
Associated with Disease Aggressiveness
|
Diagnostic
|
More Aggressive Vs Controls
|
Discovery Set: p= 0.0000638
|
Blood
|
21467234
|
619
|
Mutation Status of FBXO34 (SNP: rs2341883 (A/G))
|
Mutation
|
Humans
|
Associated with Disease Aggressiveness
|
Diagnostic
|
More Aggressive Vs Controls
|
Discovery Set: p= 0.0000638 ; Testing Set: 0.01
|
Blood
|
21467234
|
620
|
Mutation Status of HERC2 (SNP: rs6497287 (T/C))
|
Mutation
|
Humans
|
Associated with Disease Aggressiveness
|
Diagnostic
|
More Aggressive Vs Controls
|
Discovery Set: p= 0.000052 ; Test Set: p=0.004
|
Blood
|
21467234
|
621
|
Mutation Status of WWOX (SNP: rs11150069 (C/A))
|
Mutation
|
Humans
|
Associated with Disease Aggressiveness
|
Diagnostic
|
More Aggressive Vs Controls
|
Discovery Set: p= 0.00000943
|
Blood
|
21467234
|
622
|
Mutation Status of WWOX (SNP: rs4628973 (A/G))
|
Mutation
|
Humans
|
Associated with Disease Aggressiveness
|
Diagnostic
|
More Aggressive Vs Controls
|
Discovery Set: p= 0.000000462
|
Blood
|
21467234
|
623
|
Mutation Status of IL1RAPL1 (SNP: rs225061 (G/T))
|
Mutation
|
Humans
|
Associated with Disease Aggressiveness
|
Diagnostic
|
More Aggressive Vs Controls
|
Discovery Set: p= 0.000971
|
Blood
|
21467234
|
624
|
Mutation Status of TNFSF10 (SNP: rs3774315 (A/G))
|
Mutation
|
Humans
|
Associated with Disease Aggressiveness
|
Diagnostic
|
Less Aggressive Vs Controls
|
Discovery Set: 0.0000734; Testing Set: p=0.002
|
Blood
|
21467234
|
625
|
Mutation Status of FBXO34 (SNP: rs2341883 (A/G))
|
Mutation
|
Humans
|
Associated with Disease Aggressiveness
|
Diagnostic
|
Less Aggressive Vs Controls
|
Discovery Set: p= 0.0000638 ; Testing Set: 0.01
|
Blood
|
21467234
|
674
|
Circulating Tumor Cells (Base Line)
|
Others
|
Humans
|
NA
|
Predictive
|
Progression to Hormone-sensitive Prostate Cancer after ADT
|
p<0.001
|
Blood
|
21705286
|
675
|
Circulating Tumor Cells (Post Base Line)
|
Others
|
Humans
|
NA
|
Potential Predictive
|
Progression to Hormone-sensitive Prostate Cancer after ADT
|
p<0.001
|
Blood
|
21705286
|
676
|
Alkaline Phosphate
|
Others
|
Humans
|
NA
|
Potential Predictive
|
Progression to Hormone-sensitive Prostate Cancer after ADT
|
p=0.006
|
Blood
|
21705286
|
677
|
Lactate Dehydrogenase (LDH)
|
Others
|
Humans
|
NA
|
Potential Predictive
|
Progression to Hormone-sensitive Prostate Cancer after ADT
|
p<0.001
|
Blood
|
21705286
|
678
|
Testosterone
|
Others
|
Humans
|
NA
|
Potential Predictive
|
Progression to Hormone-sensitive Prostate Cancer after ADT
|
p=0.005
|
Blood
|
21705286
|
705
|
PCA3
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Controls
|
NA
|
Blood
|
21832279
|
724
|
Mutation Status of PER1, SNP: rs885747
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs More Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
725
|
Mutation Status of PER1, SNP rs2289591 - T/T Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs More Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
726
|
Mutation Status of PER1, SNP: rs885747 - G/T + T/T Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs More Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
727
|
Mutation Status of PER2, SNP: rs7602358: T/G phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Less Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
728
|
Mutation Status of PER2, SNP: rs7602358: T/G+G/G phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Less Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
729
|
Mutation Status of PER3,SNP: rs1012477: C/G phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Less Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
730
|
Mutation Status of PER3,SNP: rs1012477: C/G + C/C phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Less Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
731
|
Mutation Status of CSNK1E SNP: rs1534891: T/T phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Cancer
|
p<0.05
|
Blood
|
19934327
|
732
|
Mutation Status of CSNK1E SNP: rs1534891: T/T phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Less Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
733
|
Mutation Status of CRY1 SNP: rs12315175 ; C/C Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Less Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
734
|
Mutation Status of ARNTL, SNP: rs795022; G/A Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Cancer
|
p<0.05
|
Blood
|
19934327
|
735
|
Mutation Status of ARNTL, SNP: rs795022; G/A+A/A Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Cancer
|
p<0.05
|
Blood
|
19934327
|
736
|
Mutation Status of ARNTL, SNP: rs795022; G/A Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Less Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
737
|
Mutation Status of ARNTL, SNP: rs795022; G/A+A/A Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Less Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
738
|
Mutation Status of CLOCK, SNP: rs11133373, G/G Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs More Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
739
|
Mutation Status of CLOCK, SNP: rs11133373, G/G + C/G Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs More Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
740
|
Mutation Status of NPAS2, SNP: rs1369481, G/A Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Cancer
|
p<0.05
|
Blood
|
19934327
|
741
|
Mutation Status of NPAS2, SNP: rs1369481, G/A+A/APhenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Cancer
|
p<0.05
|
Blood
|
19934327
|
742
|
Mutation Status of NPAS2, SNP: rs1369481, G/A Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Less Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
743
|
Mutation Status of NPAS2, SNP: rs1369481, G/A+A/APhenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Less Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
744
|
Mutation Status of NPAS2, SNP: rs895521 G/A Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Cancer
|
p<0.05
|
Blood
|
19934327
|
745
|
Mutation Status of NPAS2, SNP: rs1369481, G/A+A/APhenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Cancer
|
p<0.05
|
Blood
|
19934327
|
746
|
Mutation Status of NPAS2, SNP: rs1369481, G/A+A/APhenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs More Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
747
|
Mutation Status of NPAS2, SNP: rs1369481, T/C Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Cancer
|
p<0.05
|
Blood
|
19934327
|
748
|
Mutation Status of NPAS2, SNP: rs1369481, T/C + CC Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Cancer
|
p<0.05
|
Blood
|
19934327
|
749
|
Mutation Status of NPAS2, SNP: rs1369481, T/C Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Less Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
750
|
Mutation Status of NPAS2, SNP: rs1369481, C/C Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Less Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
751
|
Mutation Status of NPAS2, SNP: rs1369481, T/C+C/C Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Less Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
773
|
Catalase
|
Protein
|
Humans
|
Downregulated in PCA
|
Diagnostic
|
Controls Vs Patients
|
p<0.05
|
Blood
|
21993000
|
774
|
Superoxide Dismutase
|
Protein
|
Humans
|
Upregulated in PCA
|
Diagnostic
|
Controls Vs Patients
|
p<0.05
|
Blood
|
21993000
|
800
|
PRKAR1A; LRRN3; PCDH17; TTN; LAIR2; RNASE3; CEACAM6; AZU1; HIST1H4C; PGLYRP1; CEACAM8; LCN2; MPO; CAMP; DEFA1;DEFA1; DEFA1; DEFA3; DEFA1; DEFA1; CTSG; DEFA4; ELA2;
|
mRNA
|
Humans
|
Downregulated (0.6-0.82 fold): [PRKAR1A; LRRN3; PCDH17; TTN;] ; Upregulated (0.6 - 1.36 fold): [LAIR2; RNASE3; CEACAM6; AZU1; HIST1H4C; PGLYRP1; CEACAM8; LCN2; MPO; CAMP; DEFA1e;DEFA1e; DEFA1e; DEFA3; DEFA1e; DEFA1e; CTSG; DEFA4; ELA2;]
|
Prognostic
|
Long-term survivors (survived for >900 days) Vs Short-Term survivors (died within 300 days) - prevaccination
|
p< 0.008
|
Blood
|
22071976
|
801
|
LTB; OLR1; CEACAM1; ARG1; MYL4; ALAS2; SLPI; SELENBP1; SNCA; AZU1; HMGXB4; RNASE3; HBQ1; MMP9; GYPE; SNCA; EPB42; HP; IFIT1L; BPI; CEACAM6; MPO; OLFM4; HBM; ALAS2; CEACAM8; CA1; HBD; LCN2; CTSG; DEFA1; CAMP; ELA2; DEFA4; DEFA3; DEFA1; DEFA1; DEFA1; DEFA1;
|
mRNA
|
Humans
|
Downregulated: [LTB (1.03 fold)] ; Upregulated (1.04- 2.87 fold): [OLR1; CEACAM1; ARG1; MYL4; ALAS2; SLPI; SELENBP1; SNCAe; AZU1; HMGXB4; RNASE3; HBQ1; MMP9; GYPE; SNCAe; EPB42; HP; IFIT1L; BPI; CEACAM6; MPO; OLFM4; HBM; ALAS2; CEACAM8; CA1; HBD; LCN2; CTSG; DEFA1e; CAMP; ELA2; DEFA4; DEFA3; DEFA1e; DEFA1e; DEFA1e; DEFA1e;]
|
Prognostic
|
Long-term survivors (survived for >900 days) Vs Short-Term survivors (died within 300 days) - Postvaccination
|
p< 0.008
|
Blood
|
22071976
|
802
|
RNASE2; SLC4A1; HEMGN; CEACAM1; S100P; ALS2; ARG1; SLPI; OLR1; RETN; HBQ1; ALAS2; MMP9; RNASE3; HMGXB4; SELENBP1; GYPE; BPI; TCN1; ORM1; CEACAM6; SNCA; MPO; SNCA; HP; CD24; IFIT1L; EPB42; CTSG; ELA2; PGLYRP1; DEFA1; CEACAM8; HBM; DEFA4; ALAS2; CAMP; LCN2; OLFM4; DEFA3; DEFA1; DEFA1; DEFA1; ERAF; CA1; HBD; DEFA1;
|
mRNA
|
Humans
|
Upregulated Postvaccine treatment: [RNASE2; SLC4A1; HEMGN; CEACAM1; S100P; ALS2; ARG1; SLPI; OLR1; RETN; HBQ1; ALAS2; MMP9; RNASE3; HMGXB4; SELENBP1; GYPE; BPI; TCN1; ORM1; CEACAM6; SNCA; MPO; HP; CD24; IFIT1L; EPB42; CTSG; ELA2; PGLYRP1; DEFA1; CEACAM8; HBM; DEFA4; CAMP; LCN2; OLFM4; DEFA3; DEFA1;ERAF; CA1; HBD;]
|
Predictive
|
Short Term Survival Pre Vs Post Vaccination
|
p< 0.008
|
Blood
|
22071976
|
803
|
LRRN3+PCDH17+HIST1H4C+PGLYRP1
|
mRNA
|
Humans
|
Downregulated: [LRRN3; PCDH17;] ; Upregulated: [HIST1H4C; PGLYRP1;]
|
Prognostic
|
Long-term survivors (survived for >900 days) Vs Short-Term survivors (died within 300 days) - prevaccination
|
p< 0.008
|
Blood
|
22071976
|
807
|
%p2PSA
|
Protein
|
Humans
|
Upregulated in Gleason Score ≥7
|
Prognostic
|
Gleason Score ≥7 and Gleason Score <7
|
p<0.0001
|
Blood
|
22078333
|
808
|
Prostate Helth Index (phi)
|
Protein
|
Humans
|
Upregulated in Gleason Score ≥7
|
Prognostic
|
Gleason Score ≥7 and Gleason Score <7
|
p<0.0001
|
Blood
|
22078333
|
809
|
%p2PSA
|
Protein
|
Humans
|
Upregulated with GS upgrading
|
Prognostic
|
Gleason sum upgrading from 6 to 7
|
p<0.0001
|
Blood
|
22078333
|
810
|
Prostate Helth Index (phi)
|
Protein
|
Humans
|
Upregulated with GS upgrading
|
Prognostic
|
Gleason sum upgrading from 6 to 7
|
p<0.0001
|
Blood
|
22078333
|
811
|
%p2PSA
|
Protein
|
Humans
|
Upregulated in Tumor Stage pt3
|
Prognostic
|
pathological stage pt2 Vs pathological stage pt3
|
p<0.0001
|
Blood
|
22078333
|
812
|
Prostate Helth Index (phi)
|
Protein
|
Humans
|
Upregulated in Tumor Stage pt3
|
Prognostic
|
pathological stage pt2 Vs pathological stage pt3
|
p<0.0001
|
Blood
|
22078333
|
896
|
Ring finger protein 19A (RNF19A)
|
mRNA
|
Humans
|
Upregulated in PCa (>2 fold)
|
Diagnostic
|
Prostate Cancer vs healthy controls
|
p = 0.0066
|
Blood
|
22493721
|
941
|
Mutation Status of KLK3 (-5429 T/G (rs2569733))
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical Recurrence Vs no Biochemical Recurrence (5 years)
|
Univariate Analysis: <0.01 ; Multivariate Analysis : p=0.013
|
Blood
|
22759231
|
942
|
Mutation Status of KLK2 (Arg250Trp (rs198977))
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical Recurrence Vs no Biochemical Recurrence (5 years)
|
Univariate Analysis: p=0.025 ; Multivariate Analysis : p=0.044
|
Blood
|
22759231
|
943
|
Mutation Status of SULT1A1, Arg213His (rs9282861)
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical Recurrence Vs no Biochemical Recurrence (5 years)
|
Univariate Analysis: 0.014
|
Blood
|
22759231
|
944
|
Mutation Status of BGLAP, -198 T/C (rs1800247)
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical Recurrence Vs no Biochemical Recurrence (5 years)
|
Univariate Analysis: <0.01 ; Multivariate Analysis : p=0.020
|
Blood
|
22759231
|
945
|
Mutation Status of KLK3 + KLK2 + SULT1A1 + BGLAP + Nonogram
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical Recurrence Vs no Biochemical Recurrence (5 years)
|
p<0.001
|
Blood
|
22759231
|
996
|
GPX1
|
mRNA
|
Humans
|
Upregulated in Metatstasis
|
Prognostic
|
Relpase Vs No Relapse
|
p<0.001
|
Blood
|
23046102
|
997
|
SOD2
|
mRNA
|
Humans
|
Upregulated in Metatstasis
|
Prognostic
|
Relpase Vs No Relapse
|
p=0.01
|
Blood
|
23046102
|
998
|
AR
|
mRNA
|
Humans
|
Differentially Expressed
|
Prognostic
|
Relpase Vs No Relapse
|
p=0.001
|
Blood
|
23046102
|
999
|
Cyclin B
|
mRNA
|
Humans
|
Differentially Expressed
|
Prognostic
|
Relpase Vs No Relapse
|
p=0.007
|
Blood
|
23046102
|
1000
|
bFGF
|
mRNA
|
Humans
|
Differentially Expressed
|
Prognostic
|
Relpase Vs No Relapse
|
p=0.004
|
Blood
|
23046102
|
1001
|
2 or more out of (GPX1; SOD2; AR; Cyclin B; bFGF)
|
mRNA
|
Humans
|
Differentially Expressed
|
Prognostic
|
Relpase Vs No Relapse
|
p<0.001
|
Blood
|
23046102
|
1002
|
ABL2+SEMA4D+ITGAL+C1QA+TIMP1+CDKN1A
|
mRNA
|
Humans
|
NA
|
Prognostic
|
low-risk group Vs high-risk group
|
p<0.05
|
Blood
|
23059047
|
1003
|
CRTAM (cytotoxic and regulatory T cell molecule) + SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)
|
mRNA
|
Humans
|
Downregulated (1.58 fold)
|
Diagnostic
|
Controls Vs High Grade Prostate Cancer (GS 8 and above)
|
p = 0.0000346
|
Blood
|
23071848
|
1004
|
CXCR3 [chemokine (C-X-C motif) receptor 3] + SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)
|
mRNA
|
Humans
|
Downregulated (1.59 fold)
|
Diagnostic
|
Controls Vs High Grade Prostate Cancer (GS 8 and above)
|
p=0.0000338
|
Blood
|
23071848
|
1005
|
FCRL3 (Fc receptor-like 3)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)
|
mRNA
|
Humans
|
Downregulated (1.61 fold)
|
Diagnostic
|
Controls Vs High Grade Prostate Cancer (GS 8 and above)
|
p = 0.00000285
|
Blood
|
23071848
|
1006
|
KIAA1143+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)
|
mRNA
|
Humans
|
Downregulated (1.44 fold)
|
Diagnostic
|
Controls Vs High Grade Prostate Cancer (GS 8 and above)
|
p = 0.000000182
|
Blood
|
23071848
|
1007
|
KLF12 (Kruppel-like factor 12)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)
|
mRNA
|
Humans
|
Downregulated (1.66 fold)
|
Diagnostic
|
Controls Vs High Grade Prostate Cancer (GS 8 and above)
|
p=0.000000816
|
Blood
|
23071848
|
1008
|
TMEM204 (transmembrane protein 204)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)
|
mRNA
|
Humans
|
Downregulated (1.52 fold)
|
Diagnostic
|
Controls Vs High Grade Prostate Cancer (GS 8 and above)
|
p = 0.000084
|
Blood
|
23071848
|
1009
|
Combination of 6 genes duplexes [CRTAM (cytotoxic and regulatory T cell molecule) + SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)] + [CXCR3 [chemokine (C-X-C motif) receptor 3] + SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)] + [FCRL3 (Fc receptor-like 3)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)] + [KIAA1143+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)] + [KLF12 (Kruppel-like factor 12)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)] + [TMEM204 (transmembrane protein 204)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)]
|
mRNA
|
Humans
|
Downregulated (1.52 fold)
|
Diagnostic
|
Controls Vs High Grade Prostate Cancer (GS 8 and above)
|
p = 0.000084
|
Blood
|
23071848
|
1010
|
PSA +CRTAM (cytotoxic and regulatory T cell molecule)+ CXCR3 [chemokine (C-X-C motif) receptor 3]+ FCRL3 (Fc receptor-like 3) + KIAA1143+ KLF12 (Kruppel-like factor 12)+ TMEM204 (transmembrane protein 204)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)
|
mRNA
|
Humans
|
Downregulated (1.52 fold)
|
Diagnostic
|
Controls Vs High Grade Prostate Cancer (GS 8 and above)
|
p = 0.000084
|
Blood
|
23071848
|
1011
|
PSA +CRTAM (cytotoxic and regulatory T cell molecule)+ CXCR3 [chemokine (C-X-C motif) receptor 3]+ FCRL3 (Fc receptor-like 3)+ KIAA1143+ KLF12 (Kruppel-like factor 12)+ TMEM204 (transmembrane protein 204)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)
|
mRNA
|
Humans
|
Downregulated (1.52 fold)
|
Diagnostic
|
Controls Vs High Grade Prostate Cancer (GS 8 and above)
|
p = 0.000084
|
Blood
|
23071848
|
1046
|
Hemoglobin
|
Others
|
Humans
|
NA
|
Diagnostic
|
PC (all stages) vs. non-cancerous conditions
|
p < 0.05
|
Blood
|
23356551
|
1048
|
blood urea nitrogen (BUN)
|
Others
|
Humans
|
NA
|
Diagnostic
|
PC (all stages) vs. non-cancerous conditions
|
p < 0.05
|
Blood
|
23356551
|
1051
|
Hemoglobin
|
Others
|
Humans
|
NA
|
Diagnostic
|
PC (stage II, III, IV) vs. other (PC stage I, PIN, BPH, prostatitis)
|
p < 0.001
|
Blood
|
23356551
|
1052
|
Hematuria
|
Others
|
Humans
|
NA
|
Diagnostic
|
PC (stage II, III, IV) vs. other (PC stage I, PIN, BPH, prostatitis)
|
p < 0.05
|
Blood
|
23356551
|
1053
|
RBC
|
Others
|
Humans
|
NA
|
Diagnostic
|
PC (stage II, III, IV) vs. other (PC stage I, PIN, BPH, prostatitis)
|
p < 0.05
|
Blood
|
23356551
|
1055
|
Circulating Tumor Cells (CTC)
|
Others
|
Humans
|
Upregulated in mRCPC (CTC count >=3)
|
Prognostic
|
Locally Advanced Prostate Cancer (LaPC) Vs Metastatic Disease
|
p < 0.001
|
Blood
|
23358719
|
1056
|
Circulating Tumor Cells (CTC)
|
Others
|
Humans
|
Upregulated in patients with Lower Overall Survival (CTC count >=3)
|
Prognostic
|
Overall Survival
|
p = 0.001
|
Blood
|
23358719
|
1143
|
RFX6 (rs339331)
|
Mutation
|
Humans
|
Reduced Risk of Prostate cancer
|
Diagnostic
|
Cancer Vs Normal
|
p= 0.013
|
Blood
|
23803082
|
1177
|
Genetic Risk score based on 41 SNPs (rs10187424, rs721048, rs1465618, rs13385191, rs12621278, rs2292884, rs4857841, rs6763931, rs10936632, rs17021918, rs12500426, rs7679673, rs2121875, rs12653946, rs130067, rs1983891, rs339331, rs9364554, rs10486567, rs6465657, rs1512268, rs1447295, rs6983561, rs16901979, rs10086908, rs12543663, rs620861, rs6983267, rs16902094, rs1016343, rs13252298, rs445114, rs10993994, rs4962416, rs10896449, rs11228565, rs12418451, rs10875943, rs9600079, rs4430796, rs11649743, rs1859962, rs8102476, rs17632542, rs2735839, rs9623117, rs5759167, rs5945619, rs5919432)
|
Mutation
|
Humans
|
Increased Score with Increased risk of Prostate Cancer
|
Diagnostic
|
Prostate Cancer Vs no Prostate Cancer
|
Univariate: p=0.014; Multivariate: 0.029
|
Blood
|
23891454
|
1178
|
SLCO2B1 rs12422149 (GG allele)
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Time to Progression
|
p =0.028
|
Blood
|
23896625
|
1208
|
RNASEL [D541E variant: GG]
|
Mutation
|
Humans
|
Expressed in patients with High Risk of PCa
|
Prognostic
|
High Risk with GG phenotype Vs High Risk with (TG and TT phenotype)
|
p≤ 0.001
|
Blood
|
24046815
|
1209
|
RNASEL [R462Q variant: AA]
|
Mutation
|
Humans
|
Expressed in patients with High Risk of PCa
|
Prognostic
|
High Risk with AA phenotype Vs High Risk with (AA and GA phenotype)
|
p≤ 0.001
|
Blood
|
24046815
|
1210
|
Copy Number Variation: Deletion of 2p24.3
|
Mutation
|
Humans
|
Deletion found in Hispanic patients with High Risk PCa
|
Prognostic
|
High Risk Vs Low Risk
|
p = 0.007
|
Blood
|
24054869
|
1249
|
Lactate Dehydrogenase [LDH]
|
Protein
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Survival
|
Univariate: p < 0.001; Multivariate: p =0.023
|
Blood
|
24255071
|
1250
|
Lactate Dehydrogenase [LDH]
|
Protein
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Survival
|
Univariate: p = 0.006
|
Blood
|
24255071
|
1308
|
C2orf43 [SNP: rs13385191]
|
Mutation
|
Humans
|
Decreased risk of PCa Specific Mortality
|
Prognostic
|
PCa Specific Mortality Vs No Mortality
|
p=0.05
|
Blood
|
24411283
|
1309
|
PDLIM5 [SNP: rs17021918]
|
Mutation
|
Humans
|
Decreased risk of PCa Specific Mortality
|
Prognostic
|
PCa Specific Mortality Vs No Mortality
|
p=0.01
|
Blood
|
24411283
|
1310
|
JAZF1 [SNP: rs10486567]
|
Mutation
|
Humans
|
Decreased risk of PCa Specific Mortality
|
Prognostic
|
PCa Specific Mortality Vs No Mortality
|
p=0.001
|
Blood
|
24411283
|
1311
|
LMTK2 [SNP: rs6465657]
|
Mutation
|
Humans
|
Decreased risk of PCa Specific Mortality
|
Prognostic
|
PCa Specific Mortality Vs No Mortality
|
p=0.02
|
Blood
|
24411283
|
1312
|
MSMB [SNP: rs10993994]
|
Mutation
|
Humans
|
Decreased risk of PCa Specific Mortality
|
Prognostic
|
PCa Specific Mortality Vs No Mortality
|
p=0.02
|
Blood
|
24411283
|
1313
|
SNP: rs7127900
|
Mutation
|
Humans
|
Decreased risk of PCa Specific Mortality
|
Prognostic
|
PCa Specific Mortality Vs No Mortality
|
p=0.01
|
Blood
|
24411283
|
1314
|
SNP: rs11672691
|
Mutation
|
Humans
|
Increased risk of PCa Specific Mortality
|
Prognostic
|
PCa Specific Mortality Vs No Mortality
|
p=0.007
|
Blood
|
24411283
|
1315
|
KLK3 [SNP: rs2735839]
|
Mutation
|
Humans
|
Decreased risk of PCa Specific Mortality
|
Prognostic
|
PCa Specific Mortality Vs No Mortality
|
p=0.002
|
Blood
|
24411283
|
1316
|
FRK [SNP: rs171866: AA versus gg/gA]
|
Mutation
|
Humans
|
Increased risk of Progression
|
Prognostic
|
Progression Vs No Progression During ADT
|
p=0.015
|
Blood
|
24448834
|
1317
|
DAB2 [SNP: rs268091: GC/CC versus GG]
|
Mutation
|
Humans
|
Increased risk of Progression
|
Prognostic
|
PCa Specific Mortality Vs No Mortality During ADT
|
p=0.012
|
Blood
|
24448834
|
1318
|
DAB2 [SNP: rs268091: CC versus GG/GC]
|
Mutation
|
Humans
|
Increased risk of Progression
|
Prognostic
|
PCa Specific Mortality Vs No Mortality During ADT
|
p=0.031
|
Blood
|
24448834
|
1319
|
EXOC4: [SNP: rs1149558: TT versus CC/CT]
|
Mutation
|
Humans
|
Increased risk of Progression
|
Prognostic
|
PCa Specific Mortality Vs No Mortality During ADT
|
p=0.014
|
Blood
|
24448834
|
1320
|
EXOC4: [SNP: rs1149558: TT versus CC/CT]
|
Mutation
|
Humans
|
Increased risk of Progression
|
Prognostic
|
All Cause Mortality Vs No Mortality during ADT
|
p=0.005
|
Blood
|
24448834
|
1354
|
COMT [SNP: rs11705619: T>C]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.041
|
Blood
|
24682418
|
1355
|
COMT [SNP: rs165849: A>G]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.047
|
Blood
|
24682418
|
1356
|
COMT [SNP: rs9332377: C>T]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.017
|
Blood
|
24682418
|
1357
|
CYP1B1 [SNP: rs1800440: A>G]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.016
|
Blood
|
24682418
|
1358
|
NQO1 [SNP: rs2917670: G>A]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.039
|
Blood
|
24682418
|
1359
|
NQO2 [SNP: rs10223369: C>T]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.002
|
Blood
|
24682418
|
1360
|
NQO2 [SNP: rs1143684: T>C]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.030
|
Blood
|
24682418
|
1361
|
NQO2 [SNP: rs6920900 G>C]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.007
|
Blood
|
24682418
|
1362
|
SULT2B1 [SNP: rs12460535: G>A]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.017
|
Blood
|
24682418
|
1363
|
SULT2B1 [SNP: rs2665582: G>A]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.037
|
Blood
|
24682418
|
1364
|
COMT [ SNP: rs16982844: C>A]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.001
|
Blood
|
24682418
|
1365
|
CYP1B1: [SNP: rs1800440: A>G]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.0009
|
Blood
|
24682418
|
1366
|
SULT2B1: [SNP: rs10426628: G>A]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.025
|
Blood
|
24682418
|
1367
|
SULT2B1: [SNP: rs12460535: G>A]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.028
|
Blood
|
24682418
|
1368
|
SULT2B1: [SNP: rs2665582: G>A]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.07
|
Blood
|
24682418
|
1370
|
hsa-miR-337-3p; hsa-miR-330-3p; hsa-miR-339-3p; hsa-miR-124; hsa-miR-218; hsa-miR-128; hsa-miR-10a; hsa-miR-199b-5p; hsa-miR-200b; hsa-miR-15b;
|
miRNA
|
Humans
|
NA
|
Prognostic
|
High Vs Intermediate Vs Low risk
|
p<0.05
|
Blood
|
24661838
|
1384
|
mir-200c
|
miRNA
|
Humans
|
Upregulated in Non Responders (Median NR/median R): 1.6 fold
|
Predictive
|
PSA responder Vs Non Responder (Pre Docetaxel levels)
|
p=0.02
|
Blood
|
24714754
|
1385
|
mir-200b
|
miRNA
|
Humans
|
Upregulated in Non Responders (Median NR/median R): 2.7 fold
|
Predictive
|
PSA responder Vs Non Responder (Pre Docetaxel levels)
|
p=0.02
|
Blood
|
24714754
|
1386
|
mir-146a
|
miRNA
|
Humans
|
Downregulated in Non Responders (Median NR/median R): 1.4 fold
|
Predictive
|
PSA responder Vs Non Responder (Pre Docetaxel levels)
|
p=0.05
|
Blood
|
24714754
|
1387
|
mir-222
|
miRNA
|
Humans
|
Upregulated after Docetaxel treatment in Responders (1.4 fold) and Downregulated after Docetaxel treatment in Non Responders (1.1 fold)
|
Predictive
|
PSA responder Vs Non Responder -Post Docetaxel Change
|
p=0.01
|
Blood
|
24714754
|
1388
|
mir-301b
|
miRNA
|
Humans
|
Upregulated after Docetaxel treatment in Responders (1.1 fold) and in Non Responders (1.6 fold)
|
Predictive
|
PSA responder Vs Non Responder -Post Docetaxel Change
|
p=0.04
|
Blood
|
24714754
|
1389
|
mir-20a
|
miRNA
|
Humans
|
Upregulated after Docetaxel treatment in Responders (1.6 fold) and in Non Responders (1.1 fold)
|
Predictive
|
PSA responder Vs Non Responder -Post Docetaxel Change
|
p=0.04
|
Blood
|
24714754
|
1390
|
mir-200c + mir-200b + mir-146a
|
miRNA
|
Humans
|
NA
|
Predictive
|
PSA responder Vs Non Responder (Pre Docetaxel levels)
|
p=0.001
|
Blood
|
24714754
|
1391
|
mir-222 + mir-301b + mir-20a
|
miRNA
|
Humans
|
NA
|
Predictive
|
PSA responder Vs Non Responder -Post Docetaxel Change
|
p = 0.02
|
Blood
|
24714754
|
1392
|
mir-200c + mir-200b + mir-146a+ mir-222 + mir-301b + mir-20a
|
miRNA
|
Humans
|
NA
|
Predictive
|
PSA responder Vs Non Responder (Pre Docetaxel levels and Post Docetaxel Changes)
|
p=0.001
|
Blood
|
24714754
|
1407
|
MIR605 [SNP: rs2043556: GG]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: Cohort 1: p= 0.006 Cohort 1+2: p=0.01;Multivariate: Cohort 1:p = 0.005 Cohort 1+2: p=0.01
|
Blood
|
24740842
|
1408
|
MIR605 [SNP: rs2043556: AG/GG vs. AA]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: Cohort 1: p= 0.04 Cohort 1+2: p=0.02
|
Blood
|
24740842
|
1409
|
MIR605 [SNP: rs2043556: GG vs. AA/AG]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: Cohort 1: p= 0.02 Cohort 1+2: p=0.03;Multivariate: Cohort 1:p = 0.004 Cohort 1+2: p=0.01
|
Blood
|
24740842
|
1410
|
MTRR [SNP: rs9332: CT]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: Cohort 1: p= 0.008 Cohort 1+2: p=0.01
|
Blood
|
24740842
|
1411
|
MTRR [SNP: rs9332: CT/TT vs. CC]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: Cohort 1: p= 0.04 Cohort 1+2: p=0.05
|
Blood
|
24740842
|
1412
|
CDON [SNP: rs3737336: CC]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: Cohort 1: p= 0.05 Cohort 1+2: p=0.01;Multivariate: Cohort 1:p = 0.03 Cohort 2: p = 0.04 Cohort 1+2: p=0.003
|
Blood
|
24740842
|
1413
|
CDON [SNP: rs3737336: CC vs. TT/TC]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: Cohort 1+2: p=0.02;Multivariate: Cohort 1: p = 0.03; Cohort 1+2: p=0.007
|
Blood
|
24740842
|
1425
|
miR-7; miR-221;
|
miRNA
|
Humans
|
Upregulated in Early Castration Resistant Acquisition
|
Prognostic
|
Early Vs Late Castration-resistant acquisition (≤20 months and ≥60 months)
|
miR-7: p=0.034; miR-221: p=0.036;
|
Blood
|
24760272
|
1453
|
Glutathione (GSH)
|
Protein
|
Humans
|
Downregulated after treatment with SeMet for 9 months (0.22 ± 0.07 change from baseline)
|
Predictive
|
Baseline Vs 9 months later after treatment with SeMet
|
p<0.05
|
Blood
|
24938534
|
1574
|
RNASEL (SNP: rs635261)
|
Mutation
|
Humans
|
NA
|
Prognostic
|
PCa-specific mortality Vs No PCa-specific mortality
|
p= 0.002
|
Blood
|
25273821
|
1575
|
XRCC1 (SNP: rs915927)
|
Mutation
|
Humans
|
NA
|
Prognostic
|
PCa-specific mortality Vs No PCa-specific mortality
|
p=0.009
|
Blood
|
25273821
|
1576
|
AKT1 (SNP: rs2494750)
|
Mutation
|
Humans
|
NA
|
Prognostic
|
PCa-specific mortality Vs No PCa-specific mortality
|
p=0.016
|
Blood
|
25273821
|
1577
|
(Intergenic) KLK3–KLK2: [SNP: rs2735839]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Gleason Score ≤ 6 Vs Gleason Score ≥ 8
|
p=0.002
|
Blood
|
25274378
|
1578
|
JAZF1 [SNP: rs10486567]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Gleason Score ≤ 6 Vs Gleason Score ≥ 8
|
p=0.012
|
Blood
|
25274378
|
1579
|
(Intergenic) LILRB2–LILRA3 [SNP: rs103294]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Gleason Score ≤ 6 Vs Gleason Score ≥ 8
|
p=0.024
|
Blood
|
25274378
|
1580
|
(Intergenic) KLK3–KLK2: [SNP: rs2735839] (AG/GG)
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Gleason Score 7 (3+4) Vs Gleason Score 7 (4+3)
|
p=0.0002
|
Blood
|
25274378
|
1581
|
(Intergenic) KLK3–KLK2: [SNP: rs2735839] (AG+AA/GG)
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Gleason Score 7 (3+4) Vs Gleason Score 7 (4+3)
|
p=0.0005
|
Blood
|
25274378
|
1594
|
Kallikrein-related peptidase 2 [hK2]+ intact PSA+ free PSA [fPSA]+total PSA [tPSA]
|
Protein
|
Humans
|
Upregulated in GS ≤ 7
|
Prognostic
|
Gleason Score <7 and Gleason Score ≤7
|
p<0.0001
|
Blood
|
25454615
|
1599
|
Methylation Status of IL-6
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.03
|
Blood
|
26265203
|
1600
|
Methylation Status of ICAM-1
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.02
|
Blood
|
26265203
|
1601
|
Methylation Status of IFN
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.02
|
Blood
|
26265203
|
1612
|
IL2RB [SNP: rs84460; C vs T]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.006
|
Blood
|
31035590
|
1613
|
SMAD3 [SNP: rs7162912; G vs T]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.0001
|
Blood
|
31035590
|
1614
|
FOXO3 [SNP: rs7762395 C Vs T]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.002
|
Blood
|
31035590
|
1615
|
FOXO3 [SNP: rs2153960 C Vs T]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.001
|
Blood
|
31035590
|
1616
|
SMAD3 [SNP: rs9302242; A vs G]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.005
|
Blood
|
31035590
|
1617
|
IL4R [SNP: rs1805011; A vs C]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.003
|
Blood
|
31035590
|
1618
|
IL4R [SNP: rs3024586; A vs G]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.003
|
Blood
|
31035590
|
1619
|
CCL5 [SNP: rs2280789 C Vs T]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.001
|
Blood
|
31035590
|
1620
|
MMP9 [SNP: rs3918262; A Vs G]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Overall Survival
|
p=0.001
|
Blood
|
31035590
|
1621
|
VEGFR2 [SNP: rs7692791; C Vs T]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Overall Survival
|
p=0.001
|
Blood
|
31035590
|
1622
|
VEGFR2 [SNP: rs2034967; C Vs T]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Overall Survival
|
p=0.00000008
|
Blood
|
31035590
|
1646
|
NLR (neutrophil to lymphocyte ratio)
|
Others
|
Humans
|
Upregulated in TRAMP
|
Prognostic
|
Overall Survival Vs No Survival
|
p=0.0
|
Blood
|
30962764
|
1647
|
PLR (Platelet to lymphocyte ratio)
|
Others
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Overall Survival Vs No Survival
|
p=0.0
|
Blood
|
30962764
|
1648
|
LMR (lymphocyte to monocyte ratio)
|
Others
|
Humans
|
Downregulated in PCa
|
Prognostic
|
Overall Survival Vs No Survival
|
p=0.0
|
Blood
|
30962764
|
1649
|
Neutrophil
|
Others
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Survival
|
p=0.006
|
Blood
|
30962764
|
1650
|
Monocyte
|
Others
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Survival
|
p=0.006
|
Blood
|
30962764
|
1651
|
NLR (neutrophil to lymphocyte ratio)
|
Others
|
Humans
|
NA
|
Prognostic
|
Progression Free Survival Vs No Progression Free Survival
|
p=0.0
|
Blood
|
30962764
|
1652
|
NLR (neutrophil to lymphocyte ratio)
|
Others
|
Humans
|
NA
|
Prognostic
|
Recurrence Free Survival Vs No Recurrence Free Survival
|
p=0.002
|
Blood
|
30962764
|
1653
|
LMR (lymphocyte to monocyte ratio)
|
Others
|
Humans
|
NA
|
Prognostic
|
Progression Free Survival Vs No Progression Free Survival
|
p=0.0
|
Blood
|
30962764
|
1654
|
Monocyte
|
Others
|
Humans
|
NA
|
Prognostic
|
Progression Free Survival Vs No Progression Free Survival
|
p=0.006
|
Blood
|
30962764
|
1714
|
TEP1 (Telomerase Associated Protein 1) [SNP: rs1760904 GG/AA]
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.003
|
Blood
|
26238235
|
1715
|
TEP1 (Telomerase Associated Protein 1) [SNP: rs1760904 AG/AA]
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.005
|
Blood
|
26238235
|
1716
|
TEP1 (Telomerase Associated Protein 1) [SNP: rs1760904 AA vs GG]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.032
|
Blood
|
26238235
|
1717
|
TEP1 (Telomerase Associated Protein 1) [SNP: rs1760904 AG/AA Vs GG]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.002
|
Blood
|
26238235
|
1718
|
TNKS2 (Tankyrase 2) [SNP: rs1539042 CG Vs GG]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.032
|
Blood
|
26238235
|
1719
|
TNKS2 (Tankyrase 2) [SNP: rs1539042 CG/CC Vs GG]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.02
|
Blood
|
26238235
|
1749
|
Neutrophil to Lymphocyte Ratio (NLR)
|
Others
|
Humans
|
NA
|
Prognostic
|
Cancer Specific Survival Vs No Survival
|
p=0.011
|
Blood
|
30800682
|
1750
|
Neutrophil to Lymphocyte Ratio (NLR)
|
Others
|
Humans
|
Upregulated in PCa: Fold change mean(BPH: 1.470; PCa: 54.384)
|
Prognostic
|
Overall Survival Vs No Overall Survival
|
p=0.017
|
Blood
|
30800682
|
1770
|
PCA3
|
mRNA
|
Humans
|
Upregulated in Stage T3-T4
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
NA
|
Blood
|
30334974
|
1771
|
hK2
|
mRNA
|
Humans
|
Downregulated in Stage T3-T4
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
NA
|
Blood
|
30334974
|
1772
|
miR-141
|
miRNA
|
Humans
|
Upregulated in Bone Metastasis
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
NA
|
Blood
|
30334974
|
1773
|
tPSA+ hK2+ PCA3+ miR-141
|
miRNA
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs Benign prostatic hyperplasia
|
NA
|
Blood
|
30334974
|
1774
|
Small HDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00070
|
Blood
|
30352818
|
1775
|
VLDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00056
|
Blood
|
30352818
|
1776
|
Cholesterol esters in medium LDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00058
|
Blood
|
30352818
|
1777
|
Cholesterol esters to total lipids ratio in medium LDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00062
|
Blood
|
30352818
|
1778
|
Cholesterol esters in small HDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00002
|
Blood
|
30352818
|
1779
|
Cholesterol esters to total lipids ratio in small HDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00111
|
Blood
|
30352818
|
1780
|
Cholesterol esters in small LDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00107
|
Blood
|
30352818
|
1781
|
Cholesterol esters to total lipids ratio in small LDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00139
|
Blood
|
30352818
|
1782
|
Free cholesterol in IDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00057
|
Blood
|
30352818
|
1783
|
Free cholesterol in large LDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00080
|
Blood
|
30352818
|
1784
|
Free cholesterol in medium LDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00060
|
Blood
|
30352818
|
1785
|
Free cholesterol to total lipids ratio in medium HDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00055
|
Blood
|
30352818
|
1786
|
Total cholesterol in HDL3
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00109
|
Blood
|
30352818
|
1787
|
Total cholesterol in medium LDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00095
|
Blood
|
30352818
|
1788
|
Total cholesterol to total lipids ratio in medium LDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00105
|
Blood
|
30352818
|
1789
|
Total cholesterol in small HDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p<0.00001
|
Blood
|
30352818
|
1790
|
Total cholesterol to total lipids ratio in small HDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00106
|
Blood
|
30352818
|
1791
|
Total cholesterol in small LDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00132
|
Blood
|
30352818
|
1792
|
Total cholesterol to total lipids ratio in small LDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00107
|
Blood
|
30352818
|
1793
|
Total cholesterol to total lipids ratio in small VLDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00105
|
Blood
|
30352818
|
1794
|
Phospholipids in IDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00092
|
Blood
|
30352818
|
1795
|
Phospholipids to total lipids ratio in medium LDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00046
|
Blood
|
30352818
|
1796
|
Phospholipids to total lipids ratio in medium VLDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p<0.00001
|
Blood
|
30352818
|
1797
|
Phospholipids in very small VLDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00103
|
Blood
|
30352818
|
1798
|
Phospholipids to total lipids ratio in very small VLDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00013
|
Blood
|
30352818
|
1799
|
Total lipids in small HDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00035
|
Blood
|
30352818
|
1800
|
Triglycerides to total lipids ratio in medium VLDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00064
|
Blood
|
30352818
|
1801
|
Triglycerides to total lipids ratio small VLDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00055
|
Blood
|
30352818
|
1802
|
Ratio of omega-6 Fatty Acids to total Fatty Acids
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00080
|
Blood
|
30352818
|
1803
|
Ratio of saturated Fatty acids to total Fatty acids
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00006
|
Blood
|
30352818
|
1804
|
Isoleucine
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00008
|
Blood
|
30352818
|
1805
|
Leucine
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00027
|
Blood
|
30352818
|
1806
|
Tyrosine
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00003
|
Blood
|
30352818
|
1807
|
Valine
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00139
|
Blood
|
30352818
|
1808
|
Albumin
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00065
|
Blood
|
30352818
|
1889
|
Interleukin 8 [SNP: rs4073 A vs T]
|
Mutation
|
Humans
|
Isoform 2 of Eukaryotic translation initiation factor 2â€alpha kinase 4 (4 fold); Keratin type I cytoskeletal 10; SCOâ€spondin (10 fold); Serum amyloid Pâ€component (4 fold); Apolipoprotein(a) (4 fold); Keratin, type I cytoskeletal 9 (3 fold); Ig kappa chain Vâ€IV region (2.4 fold); Isoform 2 of Filamin A (2.4 fold); Keratin, type II cytoskeletal 1(2.6 fold); Keratin, type II cytoskeletal 2 epidermal (2.3 fold);
|
Diagnostic/Prognostic
|
Prostate Cancer Vs Benign Prostatic hyperplasia
|
p=0.002
|
Blood
|
30641210
|
1890
|
Interleukin 8 [SNP: rs4073 AA vs TT]
|
Mutation
|
Humans
|
Ig heavy chain Vâ€III region BRO (0.1â€fold); Alphaâ€1â€antitrypsin (0.1â€fold); Plasminogen (0.1†fold); Ig heavy chain Vâ€III region TIL (0.1â€fold); Hemopexin (0.1â€fold); Afamin (0.1â€fold); Interâ€alphaâ€trypsin inhibitor heavy chain H1 (0.1â€fold); Protein AMBP (0.1â€fold); Alphaâ€1Bâ€glycoprotein (0.03â€fold); Complement component C8 alpha chain (0.06â€fold);
|
Diagnostic/Prognostic
|
Prostate Cancer Vs Benign Prostatic hyperplasia
|
p=0.002
|
Blood
|
30641210
|
1891
|
Interleukin 8 [SNP: rs4073 AA vs. TA+TT]
|
Mutation
|
Humans
|
Downregulated in PCa: [4-(3,4-dihydro-2,2,4-trimethyl-2H-1-benzopyran-4-yl)-phenol; Estradiol; Ethyl à-hydroxymyristate trisiloxane; 1-(2,4-Dimethylphenyl)-3-(tetrahydrofuryl-2)propane; 2-amino-Imidazole-5-carboxylic acid; ] Upregulated in PCa: [1,1,3,3,5,5,7,7,9,9-decamethyl-pentasiloxane; 1,1,1,5,5,5-hexamethyl-3,3-bis[(trimethylsilyl)oxy]-Trisiloxane; Phthalic acid, bis(7-methyloctyl) ester; 4-Nitro-4’-chlorodiphenylsulfoxide; 1-Propylpentachlorotriphosphazene; 2,6-di-t-butyl-4-hydroxymethylene-2,3,5,6-detetrahydrocyclohexanone]
|
Diagnostic/Prognostic
|
Prostate Cancer Vs Benign Prostatic hyperplasia
|
p=0.03
|
Blood
|
30641210
|
1892
|
Interleukin 8 [SNP: rs1126647 TT vs AA]
|
Mutation
|
Humans
|
NA
|
Diagnostic/Prognostic
|
Prostate Cancer Vs Benign Prostatic hyperplasia
|
p=0.02
|
Blood
|
30641210
|
1893
|
Interleukin 8 [SNP: rs1126647 TT vs AA + AT]
|
Mutation
|
Humans
|
NA
|
Diagnostic/Prognostic
|
Prostate Cancer Vs Benign Prostatic hyperplasia
|
p=0.02
|
Blood
|
30641210
|